Talphera, Inc.
US ˙ NasdaqCM ˙ US00444T2096

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark A Wan. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark A Wan has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TLPH / Talphera, Inc. Director 4,592
US:CNCE / Concert Pharmaceuticals Inc 10% Owner 12,301
US:NVRO / Nevro Corp. 0
US:EPOC / Epocrates Inc Director 0
US:LPDX / Liposcience Inc 10% Owner 0
US:THLD / Threshold Pharmaceuticals, Inc. 10% Owner 2,440,202
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark A Wan. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TLPH / Talphera, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TLPH / Talphera, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2012-12-07 ACRX WAN MARK A 2,364,705 3.3100 118,235 66.2000 7,827,174 227 262.4 23,197,691 296.37
2012-12-07 ACRX WAN MARK A 52,213 3.3100 2,611 66.2000 172,825
2012-05-29 ACRX WAN MARK A 67,543 3.4000 3,377 68.0000 229,646
2012-05-29 ACRX WAN MARK A 3,631 3.4000 182 68.0000 12,345
2012-05-29 ACRX WAN MARK A 208,911 3.4000 10,446 68.0000 710,297
2012-05-29 ACRX WAN MARK A 4,613 3.4000 231 68.0000 15,684

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TLPH / Talphera, Inc. Insider Trades
Insider Sales TLPH / Talphera, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TLPH / Talphera, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2014-03-10 ACRX WAN MARK A 298,508 12.3600 14,925 247.2000 3,689,559 164 6.3700 -3,594,486 -97.42
2014-03-10 ACRX WAN MARK A 16,049 12.3600 802 247.2000 198,366
2014-03-10 ACRX WAN MARK A 509,520 12.3600 25,476 247.2000 6,297,667
2014-03-10 ACRX WAN MARK A 11,250 12.3600 562 247.2000 139,050
2014-03-07 ACRX WAN MARK A 46,661 12.3882 2,333 247.7640 578,046
2014-03-07 ACRX WAN MARK A 12,186 11.9600 609 239.2000 145,745
2014-03-07 ACRX WAN MARK A 2,508 12.3882 125 247.7640 31,070
2014-03-07 ACRX WAN MARK A 655 11.9600 33 239.2000 7,834
2014-03-07 ACRX WAN MARK A 79,645 12.3882 3,982 247.7640 986,658
2014-03-07 ACRX WAN MARK A 20,800 11.9600 1,040 239.2000 248,768
2014-03-07 ACRX WAN MARK A 1,759 12.3882 88 247.7640 21,791
2014-03-07 ACRX WAN MARK A 459 11.9600 23 239.2000 5,490

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TLPH / Talphera, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark A Wan as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-06-24 2024-06-24 4 TLPH TALPHERA, INC.
Common Stock
A - Award 2,174 4,592 89.91
2023-12-13 2023-10-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 581 2,418 31.63
2022-07-15 2022-07-15 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 15,500 36,750 72.94
2021-06-17 2021-06-17 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2021-06-17 2021-06-17 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 10,000 21,250 88.89
2020-06-16 2020-06-16 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 15,000 15,000
2020-06-16 2020-06-16 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 7,500 11,250 200.00
2019-06-25 2019-06-25 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 7,500 7,500
2019-06-25 2019-06-25 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 3,750 3,750
2018-06-14 2018-06-14 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 15,000 15,000
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -126,153 0 -100.00
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -5,713,569 0 -100.00
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -179,962 0 -100.00
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -3,347,357 0 -100.00
2017-06-15 2017-06-15 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 15,000 15,000
2016-06-22 2016-06-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock (Right to Buy)
A - Award 15,000 15,000
2015-06-24 2015-06-23 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock (Option to Buy)
A - Award 15,000 15,000
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -5,400 12,301 -30.51 12.29 -66,366 151,179
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -244,600 557,126 -30.51 12.29 -3,006,134 6,847,079
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -12,755 29,052 -30.51 12.29 -156,759 357,049
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -237,245 540,375 -30.51 12.29 -2,915,741 6,641,209
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series C Preferred Stock
C - Conversion -4,506 0 -100.00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series B Preferred Stock
C - Conversion -15,069 0 -100.00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series A Preferred Stock
C - Conversion -28,090 0 -100.00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series C Preferred Stock
C - Conversion -204,076 0 -100.00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series B Preferred Stock
C - Conversion -682,475 0 -100.00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series A Preferred Stock
C - Conversion -1,272,187 0 -100.00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 4,506 47,755 10.42
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 15,069 43,249 53.47
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 28,090 28,180 31,211.11
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 204,076 2,162,814 10.42
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 682,475 1,958,738 53.47
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 1,272,187 1,276,263 31,211.65
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8,242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4,256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8,242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4,256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8,242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4,256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8,242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4,256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8,242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4,256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8,242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4,256
2014-07-25 2014-07-24 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 15,000 15,000
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -11,250 126,153 -8.19 12.36 -139,050 1,559,251
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -509,520 5,713,569 -8.19 12.36 -6,297,667 70,619,713
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -16,049 179,962 -8.19 12.36 -198,366 2,224,330
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -298,508 3,347,357 -8.19 12.36 -3,689,559 41,373,333
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -459 137,403 -0.33 11.96 -5,490 1,643,340
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -1,759 137,862 -1.26 12.39 -21,791 1,707,862
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -20,800 6,223,089 -0.33 11.96 -248,768 74,428,144
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -79,645 6,243,889 -1.26 12.39 -986,658 77,350,546
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -655 196,011 -0.33 11.96 -7,834 2,344,292
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -2,508 196,666 -1.26 12.39 -31,070 2,436,338
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -12,186 3,645,865 -0.33 11.96 -145,745 43,604,545
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -46,661 3,658,051 -1.26 12.39 -578,046 45,316,667
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -391,359 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -1,956,794 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -1,467,595 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -8,641 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -43,206 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -32,405 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 101,264 801,726 14.46 14.00 1,417,696 11,224,164
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 2,236 17,701 14.46 14.00 31,304 247,814
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 69,267 700,462 10.97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 346,335 631,195 121.58
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 259,751 284,860 1,034.49
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 1,529 15,465 10.97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 7,647 13,936 121.59
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 5,735 6,289 1,035.20
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -379,592 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -1,897,959 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -1,423,469 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -20,408 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -102,041 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -76,531 0 -100.00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 98,219 777,620 14.46 14.00 1,375,066 10,886,680
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 5,281 41,807 14.46 14.00 73,934 585,298
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 67,184 679,401 10.97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 335,922 612,217 121.58
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 251,941 276,295 1,034.50
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 3,612 36,526 10.97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 18,060 32,914 121.58
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 13,545 14,854 1,034.76
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26,972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50,017
2013-09-13 2013-09-12 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 15,000 15,000
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -11,790 0 -100.00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -11,790 0 -100.00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -15,720 0 -100.00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -15,720 0 -100.00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Common Stock
D - Sale to Issuer -1,655,329 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series F Convertible Preferred Stock
C - Conversion -25,261 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series F Convertible Preferred Stock
C - Conversion -534,339 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series E Convertible Preferred Stock
C - Conversion -41,509 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series E Convertible Preferred Stock
C - Conversion -878,030 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock
C - Conversion -69,183 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock
C - Conversion -1,463,385 0 -100.00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
P - Purchase 9,705 83,739 13.11 9.00 87,345 753,651
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
P - Purchase 205,295 1,771,347 13.11 9.00 1,847,655 15,942,123
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
C - Conversion 72,646 74,034 5,233.86
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
C - Conversion 1,536,688 1,566,052 5,233.24
2013-01-24 3 LPDX LIPOSCIENCE INC
Common Stock
29,364
2013-01-24 3 LPDX LIPOSCIENCE INC
Common Stock
1,388
2012-12-11 2012-12-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 52,213 139,621 59.73 3.31 172,825 462,146
2012-12-11 2012-12-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 2,364,705 6,323,534 59.73 3.31 7,827,174 20,930,898
2012-08-14 2012-08-13 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
A - Award 11,790 11,790
2012-07-26 2012-07-24 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award -12,500 12,500 -50.00
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 4,151 4,151 0.12 519 519
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 188,020 188,020 0.12 23,502 23,502
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 3,268 3,268 0.12 408 408
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 60,789 60,789 0.12 7,599 7,599
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 4,613 87,408 5.57 3.40 15,684 297,187
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 208,911 3,958,829 5.57 3.40 710,297 13,460,019
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 3,631 199,174 1.86 3.40 12,345 677,192
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 67,543 3,704,712 1.86 3.40 229,646 12,596,021
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 4,151 4,151 0.12 519 519
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 188,020 188,020 0.12 23,502 23,502
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 3,268 3,268 0.12 408 408
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 60,789 60,789 0.12 7,599 7,599
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 4,613 87,408 5.57 3.40 15,684 297,187
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 208,911 3,958,829 5.57 3.40 710,297 13,460,019
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 3,631 199,174 1.86 3.40 12,345 677,192
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 67,543 3,704,712 1.86 3.40 229,646 12,596,021
2006-03-07 2006-03-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
S - Sale -1,000,000 2,440,202 -29.07 14.50 -14,500,000 35,382,929
2005-02-10 2005-02-09 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
P - Purchase 11,939 175,491 7.30 7.00 83,573 1,228,437
2005-02-10 2005-02-09 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
P - Purchase 222,059 3,264,711 7.30 7.00 1,554,413 22,852,977
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -154,607 0 -100.00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -2,875,696 0 -100.00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -114,750 0 -100.00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -2,135,250 0 -100.00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 93,877 163,552 134.74
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 1,746,126 3,042,652 134.68
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 69,675 69,675
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 1,296,526 1,296,526
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)